Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04600388 · ClinicalTrials.gov registry record
Efficacy and Safety of Nerivio for the Acute Treatment of Menstrual Migraine
A clinical trial, sponsored by Theranica.
- Completed
- Registry status
- 121
- Enrollment target
NCT04600388 is a clinical trial that has completed, run by Theranica. The registered enrollment target is 121 participants.
The verdict
NCT04600388 has completed, sponsored by Theranica.
- COMPLETED
- Registry status
- 121 participants
- Enrollment target
Study Summary
Post-marketing, retrospective, observational survey study. Users (menstruating women only) of Nerivio who have used Nerivio at least 4 times between October 2019 and December 2020 will be contacted by email and/or through an app notification and will be asked to complete a 5-minute online anonymous survey assessing satisfaction, effectiveness, and safety. Eligible users will sign an informed consent form (the consent language will appear as the first page of the survey, and participants will click either "agree" or "disagree" to the consent statement; those who click "agree" will proceed to the survey, those who click "disagree" will be brought to an exit page) and complete a survey asking about their satisfaction with Nerivio and the effectiveness and safety of the device for acute treatment of menstrual migraine. During the survey, participants will be screened to verify that they have menstrual migraine (self-reported) and have used Nerivio to treat menstrual migraines.
Interventions
- DEVICE Nerivio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 121 participants |
| Start Date | 2020-09-09 |
| Est. Completion | 2020-11-10 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04600388
The ClinicalTrials.gov registry entry for NCT04600388 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 121 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Theranica, which has 22 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Nerivio is the first listed.
NCT04600388 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04600388 about?
NCT04600388 is a clinical study titled "Efficacy and Safety of Nerivio for the Acute Treatment of Menstrual Migraine". Post-marketing, retrospective, observational survey study. Users (menstruating women only) of Nerivio who have used Nerivio at least 4 times between October 2019 and December 2020 will be contacted by email and/or through an app notification and will be asked to complete a 5-minute online anonymous ...
What is the current status of trial NCT04600388?
This trial is currently completed. The enrollment target is 121 participants. The study started on 2020-09-09. Estimated completion is 2020-11-10.
What interventions are being tested in trial NCT04600388?
The interventions under investigation include: Nerivio (DEVICE).
Who is sponsoring clinical trial NCT04600388?
This trial is sponsored by Theranica, which has 22 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.